Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

177Lu-PSMA-617

- PMLiVE

The BMJ weighs in on Avastin/Lucentis debate

The UK’s leading medical journal says Avastin should be used for wet AMD to cut costs

- PMLiVE

Novartis cancer pill makes it onto UK early access list

Joins Merck’s melanoma drug Keytruda for the MHRA’s accelerated review programme 

- PMLiVE

Novartis steps up its efforts in immuno-oncology

Dedicated R&D unit created alongside $750m collaboration with Aduro

- PMLiVE

UK to pay for GSK’s MenB vaccine after year’s delay

British firm says the deal offers ‘fair value’ to the NHS

- PMLiVE

Cancer charity partners with research council for innovation

CRUK teams up with multi-disciplinary groups to help develop new oncology products

- PMLiVE

Dendreon wins IQWiG U-turn for its immunotherapy Provenge

New data for its troubled cancer drug convinces German HTA body of its added benefit

- PMLiVE

Pricing pressures preventing UK access to MenB vaccine

GlaxoSmithKline’s Bexsero will need a dramatic price cut to gain NHS entry

- PMLiVE

Cosentyx has big impact on psoriasis, says Novartis

New data shows it to achieve clear or almost clear skin

- PMLiVE

NICE set to back Novartis’ Xolair for skin condition CSU

Issues final draft guidance on the treatment's use as an add-on for chronic spontaneous urticaria

- PMLiVE

FDA approves first biosimilar

Novartis’ Sandoz unit gains new licence for Neupogen copycat

Bristol-Myers Squibb (BMS) building

BMS signs $975m deal for Bavarian Nordic cancer vaccine

Furthers prominent position in immuno-oncology with Prostvac

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links